<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642301</url>
  </required_header>
  <id_info>
    <org_study_id>B076201836443</org_study_id>
    <nct_id>NCT03642301</nct_id>
  </id_info>
  <brief_title>Dosing of Carcinogenic Complexes After Anesthesia With Intrathecal Hyperbaric Prilocaine.</brief_title>
  <official_title>Dosing of Carcinogenic Complexes Such as Urinary O-toluidine and Hemoglobin Adducts From O-toluidine in Blood After Intrathecal Administration of 50 mg Hyperbaric Prilocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de Braine-l'Alleud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prilocaine is a very common local anesthetic that has the disadvantage of being
      metabolized to o-toluidine, a human carcinogen.

      Hyperbaric 2% prilocaine (HP), recently developped, is increasingly used for spinal
      anesthesia in ambulatory surgery. But the formation of carcinogenic metabolites induced by
      the hyperbaric prilocaine is not yet known. The aim of this study is to investigate whether
      the intrathecal administration of 50 mg hyperbaric prilocaine induces also the formation of
      carcinogenic complexes such as urinary o-toluidine and hemoglobin adducts from o-toluidine in
      blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Actual">March 27, 2019</completion_date>
  <primary_completion_date type="Actual">March 27, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin adducts from o-toluidine in blood</measure>
    <time_frame>Time 0 (before surgery)</time_frame>
    <description>Hemoglobin adducts from o-toluidine in blood is measured before surgery (at admission)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin adducts from o-toluidine in blood</measure>
    <time_frame>Time 24 hours after intrathecal prilocaine injection</time_frame>
    <description>Hemoglobin adducts from o-toluidine in blood is measured at 24 hours after intrathecal prilocaine injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary o-toluidine</measure>
    <time_frame>Time 0 (before surgery)</time_frame>
    <description>Urinary o-toluidine is measured before surgery (at admission)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary o-toluidine</measure>
    <time_frame>Time 6 hours after intrathecal prilocaine injection</time_frame>
    <description>Urinary o-toluidine is measured at 6 hours after intrathecal prilocaine injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary o-toluidine</measure>
    <time_frame>Time 12 hours after intrathecal prilocaine injection</time_frame>
    <description>Urinary o-toluidine is measured at 12 hours after intrathecal prilocaine injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary o-toluidine</measure>
    <time_frame>Time 24 hours after intrathecal prilocaine injection</time_frame>
    <description>Urinary o-toluidine is measured at 24 hours after intrathecal prilocaine injection</description>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Anesthesia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood (2 samples) and Urine (4 samples)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient scheduled for an ambulatory surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : &gt; 18 years and &lt; 80years

          -  American Society of Anesthesiology (ASA) score : I-II

          -  Height between 160cm and 180cm

        Exclusion Criteria:

          -  Cardiac Disease (Aortic stenosis, heart failure...)

          -  coagulation disorder (International Normalized Ratio (INR) &gt; 1.3; platelets &lt;80
             000/mm³)

          -  Allergic to local anesthetics

          -  Smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Guntz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Université Libre de Bruxelles (ULB), Braine-l'Alleud Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Panayota Kapessidou, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Braine-l'Alleud Hospital</name>
      <address>
        <city>Braine-l'Alleud</city>
        <zip>1420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Gaber K, Harréus UA, Matthias C, Kleinsasser NH, Richter E. Hemoglobin adducts of the human bladder carcinogen o-toluidine after treatment with the local anesthetic prilocaine. Toxicology. 2007 Jan 5;229(1-2):157-64. Epub 2006 Oct 29.</citation>
    <PMID>17129655</PMID>
  </reference>
  <reference>
    <citation>Camponovo C, Fanelli A, Ghisi D, Cristina D, Fanelli G. A prospective, double-blinded, randomized, clinical trial comparing the efficacy of 40 mg and 60 mg hyperbaric 2% prilocaine versus 60 mg plain 2% prilocaine for intrathecal anesthesia in ambulatory surgery. Anesth Analg. 2010 Aug;111(2):568-72. doi: 10.1213/ANE.0b013e3181e30bb8. Epub 2010 Jun 7.</citation>
    <PMID>20529983</PMID>
  </reference>
  <reference>
    <citation>Guntz E, Latrech B, Tsiberidis C, Gouwy J, Kapessidou Y. ED50 and ED90 of intrathecal hyperbaric 2% prilocaine in ambulatory knee arthroscopy. Can J Anaesth. 2014 Sep;61(9):801-7. doi: 10.1007/s12630-014-0189-7. Epub 2014 Jun 7.</citation>
    <PMID>24906303</PMID>
  </reference>
  <reference>
    <citation>Gebhardt V, Herold A, Weiss C, Samakas A, Schmittner MD. Dosage finding for low-dose spinal anaesthesia using hyperbaric prilocaine in patients undergoing perianal outpatient surgery. Acta Anaesthesiol Scand. 2013 Feb;57(2):249-56. doi: 10.1111/aas.12031. Epub 2012 Nov 30.</citation>
    <PMID>23199005</PMID>
  </reference>
  <reference>
    <citation>Böhm F, Schmid D, Denzinger S, Wieland WF, Richter E. DNA adducts of ortho-toluidine in human bladder. Biomarkers. 2011 Mar;16(2):120-8. doi: 10.3109/1354750X.2010.534556. Epub 2010 Nov 30. Erratum in: Biomarkers. 2011 May;16(3):288.</citation>
    <PMID>21117897</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemoglobin adducts from o-toluidine in blood</keyword>
  <keyword>Urinary o-toluidine</keyword>
  <keyword>Intrathecal anesthesia</keyword>
  <keyword>Hyperbaric prilocaine</keyword>
  <keyword>Ambulatory surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

